Drug Discovery Platforms Cooperation Division
Discovery of seed/lead compounds by HTS and medicinal chemistry for development of new drugs
Division Director
Minoru Yoshida D.Agr.
- 1986
- Ph.D., University of Tokyo
- 1986
- Assistant Professor, University of Tokyo
- 1995
- Associate Professor, University of Tokyo
- 2002
- Chief Scientist, Chemical Genetics Laboratory, RIKEN
- 2002
- Visiting Professor, University of Tokyo (-current)
- 2003
- Visiting Professor, Saitama University (-current)
- 2008
- Group Director, Chemical Genomics Research Group, RIKEN
- 2011
- Visiting Professor, Kyoto University (-current)
- 2013
- Group Director, Chemical Genomics Research Group, RIKEN Center for Sustainable Resource Science
- 2013
- Division Director, Drug Discovery Platforms Cooperation Division, RIKEN Center for Sustainable Resource Science (-current)
- 2013
- Unit Leader, Seed Compounds Exploratory Unit for Drug Discovery Platform, RIKEN Center for Sustainable Resource Science
- 2018
- Unit Leader, Drug Discovery Seed Compounds Exploratory Unit, RIKEN Center for Sustainable Resource Science
- 2020
- Deputy Director, RIKEN Center for Sustainable Resource Science
- 2025
- Unit Leader, Drug Discovery Seeds Development Unit, RIKEN Center for Sustainable Resource Science (-current)
| Main Research Fields : | Biology |
|---|---|
| Related Research Fields : | Chemistry |
| Keywords : | Chemical Biology / Epigenetics / Mode of Action / Transcriptional Regulation / Chemical Screening for Drug Discovery |
| Program : | Drug Discovery Platforms Cooperation Division  |
Outline
The increased availability of genomic sequence information has already allowed the identification of numerous novel drug targets. The next challenge lies in developing new technology and assays, to further expand and exploit available genomic information obtained from basic research, and begin translational programs that will lead towards actual application and patient treatment. Academic drug discovery has become a world-wide movement at universities and research institutions, in response to which the RIKEN launched the Drug Discovery and Medical Technology Platforms (DMP). Capitalizing on RIKEN’s excellent track record in basic science and technology, including a vast library of bioactive natural products, state of the art equipment for high throughput screening (HTS), and medicinal chemistry for hit-to-lead and lead optimization, our division aims at making innovative contributions to the academic drug discovery effort.Related Links
Teams / Units
-
- Drug Discovery Seeds Development Unit
- Unit Leader:
- Minoru Yoshida
-
- Drug Discovery Chemistry Platform Unit
- Unit Leader:
- Hiroo Koyama
